Alkphase-B

Alkphase-B

A serum-based, nonisotopic immunoassay for quantifying bone-specific alkaline phosphatase for managing patients with Paget's disease of the bone, and for monitoring response to antiresorptive therapy (e.g., oestrogen) and alendronate (Fosamax™) for preventing osteoporosis.
References in periodicals archive ?
has received reimbursement by Japan's Ministry of Health and Welfare (MHW) for Osteolinks-BAP, a serum bone turnover test based upon Metra's Alkphase-B (BAP) technology.
At designated time intervals, an aliquot was brought to room temperature and assayed for bone ALP in the Tandem-MP Ostase, Tandem-R Ostase, and Alkphase-B immunoassays.
In addition, Alkphase-B is the first serum test cleared for use as a predictor of skeletal response to hormone replacement therapy.
Amersham's co-exclusive rights will include all of Metra's currently available immunoassays: Pyrilinks and Pyrilinks-D, Alkphase-B, NovoCalcin and Prolagen-C.
Pyrilinks-D is indicated for quantitative measure of deoxypyridinoline crosslinks as an indicator of bone resorption, and Alkphase-B is indicated for use as an aid in the management of Paget's disease of bone.
Pyrilinks is indicated for measuring bone type I collagen resorption, and Alkphase-B is indicated for use as an aid in the management of Paget's disease of bone.
Alkphase-B (TM) , another Metra test previously cleared by the FDA, measures alkaline phosphatase, a by-product of osteoblasts present in blood.
Alkphase-B received marketing clearance from the US Food and Drug Administration for management of Paget's disease on August 29, 1995.
Alkphase-B received marketing clearance from US Food and Drug Administration for management of Paget's disease on August 29, 1995.
Alkphase-B measures serum levels of bone-specific alkaline phosphatase (BAP), an enzyme released into the bloodstream as a result of bone formation.
Metra Biosystems is pleased to broaden our relationship with Sumitomo with this current agreement for ALKPHASE-B," said George Dunbar, President and CEO of Metra Biosystems.
Thursday announced the introduction of ALKPHASE-B -- a new blood test that may be used to aid in the management of patients diagnosed with metabolic bone disorders.